Targeted therapy of renal cell carcinoma

Abstract

Commun Oncol 2006;3:419–420, 422–425 Summary by Matt Stenger, MS; reviewed by Nicholas J. Vogelzang, MD, Director, Nevada Cancer Institute, Las Vegas. R ecently, the US Food and Drug Administration approved two oral tyrosine kinase inhibitors, sunitinib (Sutent) and sorafenib (Nexavar), for use as single-agent therapy of metastatic renal cell carcinoma (RCC).1,2 Both of these agents target multiple growth factors that play a significant role in the spread of RCC.